9:24 AM ET
8-K
Other 8-K Filing
Cadrenal Therapeutics Other 8-K Filing
Cadrenal Therapeutics has initiated a formal strategic process to evaluate opportunities to maximize shareholder value, including potential licensing, asset sales, partnerships, or business combinations. The company has engaged Tungsten Advisors as its exclusive financial advisor following alignment with the FDA on a Phase 3 pathway for its lead asset, CAD-1005.
- Counterparty
- Tungsten Advisors